

# ASX Announcement

Medibio Limited – 13 OCT 2017



## Directors Resignation

Medibio Limited (ASX: MEB) (“Medibio” or the “Company”) announces that Mr Kris Knauer has resigned today as a Non-Executive Director of Medibio Limited.

Mr Knauer was appointed 1 July 2014 and was an executive director until the appointment of Jack Cosentino as Managing Director and CEO in February 2017. Mr Knauer resigns due to pressure of his other executive and non-executive roles and notes that with the successful capital raise and strong team Medibio is well positioned to achieve its objectives in the next 12 months.

Medibio thanks him for his valuable contribution to the Board and the company’s development.

With Mr Knauer’s resignation, the Board of Medibio now consists of:

Chris Indermaur (Non-Executive Chairman)  
Jack Cosentino (Managing Director & CEO)  
Dr Adam Darkins (Non-executive Deputy Chairman)  
Dr Frank Prendergast (Non-Executive Director)  
Andrew Maxwell (Non-Executive Director)  
Patrick Kennedy (Non-Executive Director)  
Michael Phelps (Non-Executive Director)  
Peter Carlisle (Alternate director to Michael Phelps)

### **Robert Lees**

#### **Company Secretary**

**Office:** +61 (02) 9299 9580

**Email:** [rob.lees@medibio.com.au](mailto:rob.lees@medibio.com.au)

### **About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).